1. Home
  2. UEC vs GRFS Comparison

UEC vs GRFS Comparison

Compare UEC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uranium Energy Corp.

UEC

Uranium Energy Corp.

HOLD

Current Price

$17.14

Market Cap

5.9B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.26

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEC
GRFS
Founded
2003
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
UEC
GRFS
Price
$17.14
$9.26
Analyst Decision
Strong Buy
Hold
Analyst Count
5
2
Target Price
$15.80
$10.15
AVG Volume (30 Days)
10.6M
435.4K
Earning Date
12-10-2025
07-28-2022
Dividend Yield
N/A
1.61%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
$49,750,000.00
$8,821,017,248.00
Revenue This Year
N/A
$5.36
Revenue Next Year
$153.62
$5.15
P/E Ratio
N/A
$17.59
Revenue Growth
189.19
7.31
52 Week Low
$3.85
$6.19
52 Week High
$17.80
$11.14

Technical Indicators

Market Signals
Indicator
UEC
GRFS
Relative Strength Index (RSI) 73.23 53.46
Support Level $11.65 $8.79
Resistance Level $14.59 $9.57
Average True Range (ATR) 0.92 0.23
MACD 0.43 -0.02
Stochastic Oscillator 90.96 60.26

Price Performance

Historical Comparison
UEC
GRFS

About UEC Uranium Energy Corp.

Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: